Date: 2015-10-13
Type of information: Nomination
Compound:
Company: Vedanta Biosciences (USA - MA)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 13, 2015, Vedanta Biosciences announced the addition of Lisa Rae Schopf, PhD, who has joined the Company as Head of Preclinical Development; and Erik J. Spek, PhD, who has joined as Head of Intellectual Property. Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory, and infectious diseases, which are developed using a proprietary technology platform that enables mining of the human microbiome for potent pharmaceutical products. Vedanta has foundational intellectual property issued in Japan, the site of its initial filing, and has pending patent applications in other major geographies. Dr. Schopf previously served as the Senior Director of Preclinical Development at Kala Pharmaceuticals. She has over 20 years of experience in the pharmaceutical industry focused in inflammatory diseases, immunology, and pharmacology. She has worked at Virdante Pharmaceuticals, Abbott Bioresearch Center, Millennium as well as Genetics Institute. Dr. Schopf received her B.S. in Biology from Carroll College in Wisconsin, her M.S. in the Department of Bacteriology from the University of Wisconsin, and her PhD in the Department of Animal Health & Biomedical Sciences from the University of Wisconsin. Dr. Spek joins Vedanta Biosciences from Epizyme, Inc., a clinical stage biopharmaceutical company focusing on epigenetic targets, where he served as Director of IP. Prior to Epizyme, Dr. Spek worked at Boston-based IP law firm Wolf Greenfield, focusing on prosecution, FTO, and due diligence in a variety of bio and pharma related technologies. Dr. Spek graduated cum laude from Suffolk Law School, has a B.S. in Chemistry and Philosophy from Vrije Universiteit in Amsterdam, a PhD in Biophysical Chemistry from New York University, and conducted his postdoctoral research in Biological Engineering at MIT.
Financial terms:
Latest news:
